Pragmatic Phase Iii Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

Pragmatic Phase Iii Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Recruiting
99 years or below
All
Phase 3
1493 participants needed
1 Location

Brief description of study

This is a pragmatic randomized clinical trial in which patients with locally advanced breast cancer will be randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life (HRQOL), and cancer control outcomes. We hypothesize that proton therapy, as part of multi-modality curative treatment for locally-advanced breast cancer, reduces major cardiovascular events (MCE), is non-inferior in cancer control, and improves HRQOL compared to photon therapy, the current standard treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: breast cancer
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 823761

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.